| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF835-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56708SS | |||
| Azide and BSA Free | NBP2-33244 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB835-SP | |||
| Carrier Free | IC835G-025 | |||
| Carrier Free | IC835G-100 | |||
| Carrier Free | IC835T-100UG | |||
| Carrier Free | IC835S-100UG | |||
| Carrier Free | IC835U-100UG | |||
| Carrier Free | IC835V-100UG | |||
| Carrier Free | IC835N-100UG | |||
| Carrier Free | IC835R-100UG | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56113SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB500-210SS | |||
| BSA Free | NB500-210-0.1ml | |||
| Azide and BSA Free | NBP2-80614 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56112SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF-605-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | DYC835-5 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56709SS | |||
| Azide and BSA Free | NBP2-80613 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB707-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-90125-25ul | |||
![Western Blot: Mouse Monoclonal Caspase-3 Antibody (31A1067) - (Pro and Active) [IMGENEX: IMG-144A] [NB100-56708] - Whole cell lysates from MDA-MB-231, MCF-7, SUM149 and SUM159 cells were loaded with 50 ug/lane. 10% SDS-PAGE. Caspase-3 Antibody (NB100-56708) was used for primary antibody: 1:2000, 4℃, overnight. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-56708_mouse-monoclonal-caspase-3-antibody-31a1067-pro-and-active-imgenex-img-144a-western-blot-3112024145834..png)
![Immunocytochemistry/ Immunofluorescence: Caspase-3 Antibody (31A1067) - (Pro and Active) - BSA Free [NB100-56708] - rOPN administration influenced the interaction & balance between Beclin 1 & Caspase‐3 at 24 h after SAH. Double immunofluorescence staining of Caspase‐3 & Beclin 1 in Sham group, SAH + Vehicle group & SAH + rOPN group at 24 h after SAH induction. Sample size is 9, n = 3 per group. Localization of Caspase‐3 can be cytoplasmic & nuclear. Staining in the nucleus is considered to be an indication of active Caspase‐3. The dashed lines & the red box on brain slice images indicate the locations observed. Vehicle, phosphate‐buffered saline; Scale bar = 50 μm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31436915), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56708_mouse-monoclonal-caspase-3-antibody-31a1067-pro-and-active-310202415175231.jpg)
![Western Blot: Caspase-3 Antibody (31A1067) - (Pro and Active) - BSA Free [NB100-56708] - PEM induces YIPF2 upregulation & apoptosis in NSCLC cells.a, b H1792 (a) & H1299 (b) NSCLC cells were treated with PEM at various concentrations (0–10.0 μM) for 36 h. Cell lysates were analyzed by Western blotting with antibodies against YIPF2 & ACTB. c Overexpression of YIPF2 in H1299 cells in the presence or absence of PEM at 5.0 μM for 36 h. Cell lysates were analyzed by Western blotting with antibodies against YIPF2, CASP8, CASP3, PARP1 & ACTB. d Knockdown of YIPF2 expression by YIPF2–1 siRNA in A549 NSCLC cells in the presence or absence of PEM at 5.0 μM for 36 h. Cell lysates were analyzed by Western blotting with antibodies against YIPF2, CASP8, CASP3, PARP1 & ACTB. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32303681), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56708_mouse-monoclonal-caspase-3-antibody-31a1067-pro-and-active-310202415175219.jpg)
![Western Blot: Caspase-3 Antibody (31A1067) - (Pro and Active) - BSA Free [NB100-56708] - PEM induces YIPF2 upregulation & apoptosis in NSCLC cells.a, b H1792 (a) & H1299 (b) NSCLC cells were treated with PEM at various concentrations (0–10.0 μM) for 36 h. Cell lysates were analyzed by Western blotting with antibodies against YIPF2 & ACTB. c Overexpression of YIPF2 in H1299 cells in the presence or absence of PEM at 5.0 μM for 36 h. Cell lysates were analyzed by Western blotting with antibodies against YIPF2, CASP8, CASP3, PARP1 & ACTB. d Knockdown of YIPF2 expression by YIPF2–1 siRNA in A549 NSCLC cells in the presence or absence of PEM at 5.0 μM for 36 h. Cell lysates were analyzed by Western blotting with antibodies against YIPF2, CASP8, CASP3, PARP1 & ACTB. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32303681), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56708_mouse-monoclonal-caspase-3-antibody-31a1067-pro-and-active-310202415371987.jpg)
![Immunocytochemistry/ Immunofluorescence: Caspase-3 Antibody (31A1067) - (Pro and Active) - BSA Free [NB100-56708] - Lipofection of top broccoletti-miR candidates does not influence basal & induced apoptosis.(A) BxPc-3 & Bx-Gem cells were transfected as described in Figure 3. Seventy-two hours later, the cells were stained with Annexin V-PE & 7-AAD, followed by FACS analysis. The percentage of Annexin V- & 7-AAD-positive cells is shown. (B) Lipofected BxPc-3 & Bx-Gem cells were stained with an antibody specific for the proliferation marker Ki-67 (green) or the apoptosis marker cleaved fragment of caspase-3 (red), which indicates apoptosis. Representative images at ×100 magnification are shown. The percentage of Ki-67- or caspase-3-positive cells was counted in 18 visual fields, & the means ± SD are shown in the diagram below. (C) BxPc-3 & Bx-Gem were lipofected as described above, & at 24 h later, the cells were treated with gemcitabine (10 nM) or were left untreated. Ninety-six hours after gemcitabine treatment, viability was determined by MTT assay. The data are presented as the means ± SD (**P < 0.01). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32292571), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56708_mouse-monoclonal-caspase-3-antibody-31a1067-pro-and-active-31020241612697.jpg)
![Western Blot: Caspase-3 Antibody (31A1067) - (Pro and Active) - BSA Free [NB100-56708] - PEM induces apoptosis of NSCLC cells via YIPF2-TNFRSF10B axis.a, b A549 (a) & H1792 (b) cells were treated with PEM at 5.0 μM for the indicated times (0, 6, 12, 24, 36 & 48 h). Cell lysates were analyzed by Western blotting with antibodies against YIPF2, TNFRSF10B & ACTB. c A549 cells were treated with doxorubicin (DOX) at various concentrations (0–2.0 μM) for 18 h. Cell lysates were analyzed by Western blotting with antibodies against YIPF2, TNFRSF10B & ACTB. d Overexpression of YIPF2 in H1792 & H1299 cells in the presence or absence of PEM at 5.0 μM for 36 h. Cell lysates were analyzed by Western blotting with antibodies against YIPF2, TNFRSF10B & ACTB. e Knockdown of YIPF2 expression by YIPF2–1 siRNA in A549 & H1792 cells in the presence or absence of PEM at 5.0 μM for 36 h. Cell lysates were analyzed by Western blotting with antibodies against YIPF2, TNFRSF10B & ACTB. f Overexpression of YIPF2 in H1299 cells (left) or Knockdown of YIPF2 expression by YIPF2–1 siRNA in H1792 cells (right) in the presence or absence of PEM at 5.0 μM for 36 h. Cell lysates were analyzed by Western blotting with antibodies against YIPF2, TNFRSF10A & ACTB. g Three A549 cell lines (Ctrl, YIPF2, YIPF2 + siTNFRSF10B) in the presence or absence of PEM at 5.0 μM for 36 h. Cell lysates were analyzed by Western blotting with antibodies against YIPF2, TNFRSF10B, CASP8, CASP3 & ACTB. h Three H1299 cell lines (Ctrl, siYIPF2–1, siYIPF2–1 + TNFRSF10B (short isoform)) in the presence or absence of PEM at 5.0 μM for 36 h. Cell lysates were analyzed by Western blotting with antibodies against YIPF2, TNFRSF10B, CASP8, CASP3 & ACTB. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32303681), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56708_mouse-monoclonal-caspase-3-antibody-31a1067-pro-and-active-3102024155528.jpg)
![Immunocytochemistry/ Immunofluorescence: Caspase-3 Antibody (31A1067) - (Pro and Active) - BSA Free [NB100-56708] - Cell numbers positively stained for NeuN, DCX, PCNA & caspase-3 in the subgranular region of the dentate gyrus in WT & RanBP9−/− (KO) mice.(A), DAPI-stained brain sections to show the highlighted subgranular zone within the dentate gyrus region of the hippocampus used for cell counts shown in B. (B), Representative brain sections stained with anti-NeuN, anti-DCX, anti-PCNA, anti-capsase-3 & counter stained with DAPI. Cell counting revealed significantly decreased numbers of NeuN positive cells in RanBP9−/− (KO) brains (22%) compared to WT controls. However DCX, PCNA & caspase positive cell numbers were not significantly altered. In each group, n = 3, data presented as mean± SEM. **, p<0.01 by Student’s t-test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23840553), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56708_mouse-monoclonal-caspase-3-antibody-31a1067-pro-and-active-3102024155450.jpg)
![Western Blot: Caspase-3 Antibody (31A1067) - (Pro and Active) - BSA Free [NB100-56708] - NFATc1 regulates DcR3 expression at a transcriptional level. (A,B) Immunoblot analysis of whole-cell lysates & quantitative real-time-PCR assaying relative DcR3 mRNA expression of ACHN & 769-P cells 24 h after treatment with cyclosporin A (CsA, 25 μM) or Tacrolimus (FK-506, 50 μM) (A); 48 h post transfection with NFATc1 or an empty vector control (neo) (B). Expression data were normalized to internal 18S rRNA expression (mean ± SEM; n=3; *p<0.05, **p<0.01, ***p<0.001; T-test). (C) Immunoblot analysis of cytoplasmic & nuclear fractions of ACHN & 769-P cells after treatment with LY294002 (50 μM), Everolimus (1 μM), or Cyclosporine A (25 μM). (D) Relative NFATc1–luciferase reporter activity of ACHN & 769-P cells 24 h post transfection with myrAkt or an empty vector control (neo) (mean ± SEM; n=3; *p<0.05, **p<0.01; T-test). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24107265), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56708_mouse-monoclonal-caspase-3-antibody-31a1067-pro-and-active-3102024155373.jpg)
![Western Blot: Caspase-3 Antibody (31A1067) - (Pro and Active) - BSA Free [NB100-56708] - rOPN administration elevated the expression of autophagy‐related proteins while suppressing apoptosis in rat brain at 24 h after SAH. The effects of rOPN on expression levels of (A) Beclin 1, mean ± SD is 1.016 ± 0.2262 in Sham group, 2.874 ± 1.147 in SAH + Vehicle group, 4.963 ± 2.05 in SAH + rOPN group, F = 15.52, (B) ATG5, mean ± SD is 0.8908 ± 0.2545 in Sham group, 2.332 ± 0.6431 in SAH + Vehicle group, 4.364 ± 1.309 in SAH + rOPN group, F = 25.02, (C) LC3, mean ± SD is 1 ± 0.1845 in Sham group, 1.755 ± 0.3017 in SAH + Vehicle group, 2.7 ± 0.7957 in SAH + rOPN group, F = 17.23, (D) Cleaved Caspase‐3, mean ± SD is 1.008 ± 0.186 in Sham group, 4.112 ± 1.528 in SAH + Vehicle group, 2.291 ± 0.6268 in SAH + rOPN group, F = 15.86, (E) Bax, mean ± SD is 1.006 ± 0.321 in Sham group, 37.47 ± 10.86 in SAH + Vehicle group, 23.83 ± 8.143 in SAH + rOPN group, F = 33.13, (F) Bcl‐2, mean ± SD is 1.005 ± 0.2736 in Sham group, 0.2309 ± 0.1257 in SAH + Vehicle group, 0.7843 ± 0.2278 in SAH + rOPN group, F = 20.1, in the left hemisphere of rat brain at 24 h after SAH. Sample size is 18, n = 6 per group. Data were presented as mean ± SD. *P < .05, ***P < .001 vs Sham group; #P < .05, ##P < .01 vs SAH + Vehicle group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31436915), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56708_mouse-monoclonal-caspase-3-antibody-31a1067-pro-and-active-31020241552392.jpg)
![Western Blot: Caspase-3 Antibody (31A1067) - (Pro and Active) - BSA Free [NB100-56708] - RAB8 suppresses PEM-induced apoptosis of NSCLC cells by promoting the removing of TNFRSF10B from plasma membrane to cytoplasm.a, b Knockdown of RAB8 expression by RAB8 siRNA in H1792 (a) & A549 (b) cells in the presence or absence of PEM at 5.0 μM for 36 h. The surface expression of TNFRSF10B was confirmed by flow cytometry analyses. c Overexpression of RAB8 in H1299 cells in the presence or absence of PEM at 5.0 μM for 36 h. Cell lysates were analyzed by Western blotting with antibodies against RAB8, TNFRSF10B, CASP8, CASP3, PARP1 & ACTB. d Knockdown of RAB8 expression by RAB8 siRNA in H1792 cells in the presence or absence of PEM at 5.0 μM for 36 h. Cell lysates were analyzed by Western blotting with antibodies against RAB8, TNFRSF10B, CASP8, CASP3, PARP1 & ACTB. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32303681), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56708_mouse-monoclonal-caspase-3-antibody-31a1067-pro-and-active-31020241612680.jpg)
![Western Blot: Caspase-3 Antibody (31A1067) - (Pro and Active) - BSA Free [NB100-56708] - RAB8 suppresses PEM-induced apoptosis of NSCLC cells by promoting the removing of TNFRSF10B from plasma membrane to cytoplasm.a, b Knockdown of RAB8 expression by RAB8 siRNA in H1792 (a) & A549 (b) cells in the presence or absence of PEM at 5.0 μM for 36 h. The surface expression of TNFRSF10B was confirmed by flow cytometry analyses. c Overexpression of RAB8 in H1299 cells in the presence or absence of PEM at 5.0 μM for 36 h. Cell lysates were analyzed by Western blotting with antibodies against RAB8, TNFRSF10B, CASP8, CASP3, PARP1 & ACTB. d Knockdown of RAB8 expression by RAB8 siRNA in H1792 cells in the presence or absence of PEM at 5.0 μM for 36 h. Cell lysates were analyzed by Western blotting with antibodies against RAB8, TNFRSF10B, CASP8, CASP3, PARP1 & ACTB. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32303681), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56708_mouse-monoclonal-caspase-3-antibody-31a1067-pro-and-active-31020241682182.jpg)
![<b>Biological Strategies Validation. </b>Apoptotic markers in PFII treated NHDFs.(A–C) [Ca2+]i fluorescence visualizations in cells as revealed by using an LSCM with fluorescent probe Fluo3/AM, scale bar - 100 µm. (D–F) Externalized phosphatidylserine by annexin V-fluorescein binding after PFII treatment, scale bar - 100 µm. Third (G–I) and fourth (J–L) panels show actin cytoskeletal organization and caspase-3 activation. Scale bar - 50 µm. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0057991), licensed under a CC-BY license. Not internally tested by R&D Systems.](http://images.novusbio.com/fullsize/mab835_human-mouse-cleaved-caspase-3-asp175-mab-clone-269518-4120241033306.jpg)
![<b>Biological Strategies Validation. </b>Apoptotic markers in PFII treated NHDFs.(A–C) [Ca2+]i fluorescence visualizations in cells as revealed by using an LSCM with fluorescent probe Fluo3/AM, scale bar - 100 µm. (D–F) Externalized phosphatidylserine by annexin V-fluorescein binding after PFII treatment, scale bar - 100 µm. Third (G–I) and fourth (J–L) panels show actin cytoskeletal organization and caspase-3 activation. Scale bar - 50 µm. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0057991), licensed under a CC-BY license. Not internally tested by R&D Systems.](http://images.novusbio.com/fullsize/mab835_human-mouse-cleaved-caspase-3-asp175-mab-clone-269518-41202410331936.jpg)
![Immunohistochemistry-Paraffin: Caspase-3 Antibody - (active/cleaved) [NB100-56113] - Dog ischemic brain stained for Active/Cleaved Caspase-3 expression using Caspase-3 Antibody - (active/cleaved)( NB100-56113) at 1:2000. Staining is seen in the nuclei of dying neurons (black arrow) but not in the morphologically normal nuclei (open arrows). Caspase-3 expression in the nucleus is considered to be a marker of active/caspase-3 expression and apoptosis. Hematoxylin-eosin counterstain.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-active-cleaved-Immunohistochemistry-Paraffin-NB100-56113-img0003.jpg)
![Immunohistochemistry-Paraffin: Caspase-3 Antibody - (active/cleaved) [NB100-56113] - Irradiated mouse spleen stained for Active/Cleaved Caspase-3 expression using Caspase-3 Antibody - (active/cleaved) (NB100-56113) at 1:2000. Staining is seen in the nuclei of a subset of the cell population. Caspase-3 expression in the nucleus is considered to be a marker of active/caspase-3 expression and apoptosis. Hematoxylin-eosin counterstain.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-active-cleaved-Immunohistochemistry-Paraffin-NB100-56113-img0004.jpg)
![Immunohistochemistry: Caspase-3 Antibody - (active/cleaved) [NB100-56113] - Pathology in DOX treated acute & recovery phase mice. Regions of myofiber loss & frank replacement fibrosis were noted, most commonly in atria (A, acute phase), & rarely in ventricles (D, recovery phase). These areas were accompanied by macrophage infiltration (B, E) & myofibroblast proliferation (C) consistent with fibroplasia. Rare myofibers were matrix metalloproteinase 2 (F, recovery phase animal) or caspase-3 positive (G, acute phase animal). Reticulin staining (A, D); Immunohistochemistry: Iba 1(B, E; macrophages), alpha SMA (C), MMP-2 (F) & cleaved caspase -3 (G) Bar = 100µm (A-C); 50µm (D-F); 20µm (G). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31263061), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56113_rabbit-polyclonal-caspase-3-antibody-active-cleaved-31020241530428.jpg)
![Western Blot: Caspase-3 Antibody - (active/cleaved) [NB100-56113] - Antidepressants-mediated effect on cellular protein content. HT-22 cells were treated with antidepressants for 48 & 96 h & densitometry analysis of NF-kappa B (b), p16 (c), p21 (d), p27 (e), p53 (f), TRF1 (g), TRF2 (h), calnexin (i), NuMa (j), cleaved caspase 3 (k), Bcl-2 (l) was evaluated. Representative Western Blots are presented (a). Bars indicate SD, n = 3, ***/^^^p < 0.001, **/^^p < 0.01, */^p < 0.05, no indication—no statistical significance (one-way ANOVA & Dunnett’s a posteriori test) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31278507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56113_rabbit-polyclonal-caspase-3-antibody-active-cleaved-310202415175224.jpg)
![Immunocytochemistry/ Immunofluorescence: Caspase-3 Antibody - (active/cleaved) [NB100-56113] - Morphological changes & expression of key apoptosis-related molecules in 4T1 cells after DE-EDCP treatment(A) Morphological changes of 4T1 cells exposed to various concentrations of DE-EDCP for 24h. (B) Immunofluorescence staining for Bcl-2 (green), Bax (green) & cleaved caspase-3 (green) together with DNA staining with DAPI (blue) in 4T1 cells incubated with DE-EDCP or cisplatin (31.25 μM) for 24h, as well as in untreated cells (magnification at x200). (C) mRNA expression of Bcl-2, Bax & caspase-3 quantified by RT-PCR in 4T1 cells after DE-EDCP 24h treatment. DE-EDCP treatment markedly increased the expression of Bax & caspase-3 mRNA & decreased the expression of Bcl-2 mRNA in 4T1 cells. beta -actin mRNA was used as an internal control. Data points are represented by the expression ratio & mean±SD fold of control in 4T1 cells. (* Bcl-2-: DE-EDCP vs. untreated p=0.03; DE-EDCP vs. cisplatin p=0.006; cislatin vs. untreated p=0.001; Bax-: DE-EDCP vs. untreated p=0.011; cislatin vs. untreated p=0.009; caspase-3-: DE-EDCP vs. untreated p=0.015; DE-EDCP vs. cisplatin p=0.021) Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.25610), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56113_rabbit-polyclonal-caspase-3-antibody-active-cleaved-31020241682116.jpg)
![Immunohistochemistry-Paraffin: Caspase-3 Antibody [NB600-1235] - Formalin fixed paraffin embedded human tonsil stained with Caspase-3 Antibody (NB600-1235).](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Immunohistochemistry-Paraffin-NB600-1235-img0003.jpg "Immunohistochemistry-Paraffin: Caspase-3 Antibody [NB600-1235] - Formalin fixed paraffin embedded human tonsil stained with Caspase-3 Antibody (NB600-1235).")
![Immunohistochemistry-Paraffin: Caspase-3 Antibody [NB600-1235] - Human tonsil.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Immunohistochemistry-Paraffin-NB600-1235-img0002.jpg)
![<b>Biological Strategies Validation. </b>Simple Western: Caspase-3 Antibody (CPP32 4-1-18) [NB500-210] - Lane view shows a specific band for Caspase 3 in 0.5 mg/ml of Hek293 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-CPP32-4-1-18-Simple-Western-NB500-210-img0005.jpg)
![Immunohistochemistry-Paraffin: Caspase-3 Antibody (CPP32 4-1-18) [NB500-210] - Analysis of a FFPE human spleen section using 1:200 dilution of . The staining was developed using HRP conjugated anti-mouse secondary antibody and DAB reagent. This Caspase 3 antibody generated a specific staining in the cytoplasm of various spleenocytes.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-CPP32-4-1-18-Immunohistochemistry-Paraffin-NB500-210-img0007.jpg)
![Immunohistochemistry-Paraffin: Caspase-3 Antibody (CPP32 4-1-18) [NB500-210] - Caspase-3 was detected in immersion fixed paraffin-embedded sections of human bladder 1:300 dilution of mouse monoclonal Caspase-3 Antibody (CPP32 4-1-18) (NB500-210, Novus Biologicals), for 1 hour at room temperature followed by anti-mouse IgG VisUCyte HRP polymer(VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue).](http://images.novusbio.com/fullsize/Caspase-3-Antibody-CPP32-4-1-18-Immunohistochemistry-Paraffin-NB500-210-img0006.jpg)
![Immunohistochemistry-Frozen: Caspase-3 Antibody (CPP32 4-1-18) - BSA Free [NB500-210] - Analysis of murine spleen with Caspase-3 (green), CD3 (red) and DAPI (blue). Image from verified customer review.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-CPP32-4-1-18-BSA-Free-Immunohistochemistry-Frozen-NB500-210-img0009.jpg)
![Western Blot: Caspase-3 Antibody (CPP32 4-1-18) [NB500-210] - Detection of Caspase (19 and 35 kDa) from HEK293 cell extract using (NB500-210). Lanes 1 and 2 contain inactive and active Caspase, respectively.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-CPP32-4-1-18-Western-Blot-NB500-210-img0004.jpg)
![Immunohistochemistry-Paraffin: Caspase-3 Antibody (CPP32 4-1-18) [NB500-210] - Rat epithelial cells of the tongue base. Antigen retrieval method: Citrate buffer.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-CPP32-4-1-18-Immunohistochemistry-Paraffin-NB500-210-img0001.jpg)
![Western Blot: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Analysis of Caspase-3. Lysates from Jurkat cells (lane 1), normal mammary tissue (lane 2) and surgical specimens from three invasive ductal carcinomas (lanes 3-5) were normalized for total protein content (50 ug/lane) and western blotted with Caspase-3 Antibody - (Pro and Active). The ~32 kDa pro-Caspase-3 protein was detected in all samples. Active/cleaved Caspase-3 was identified in Jurkat and two ductal carcinomas (14-21 kDa large subunit).](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Western-Blot-NB100-56112-img0010.jpg "Western Blot: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Analysis of Caspase-3. Lysates from Jurkat cells (lane 1), normal mammary tissue (lane 2) and surgical specimens from three invasive ductal carcinomas (lanes 3-5) were normalized for total protein content (50 ug/lane) and western blotted with Caspase-3 Antibody - (Pro and Active). The ~32 kDa pro-Caspase-3 protein was detected in all samples. Active/cleaved Caspase-3 was identified in Jurkat and two ductal carcinomas (14-21 kDa large subunit).")
![Immunohistochemistry-Paraffin: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Caspase-3 was detected in immersion fixed paraffin-embedded sections of human bladder tissue 1:300 dilution of rabbit polyclonal Caspase-3 Antibody - (Pro and Active)(NB100-56112), for 1 hour at room temperature followed by anti-rabbit IgG VisUCyte HRP polymer(VC003). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue).](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Immunohistochemistry-Paraffin-NB100-56112-img0011.jpg)
![Simple Western: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Simple Western lane view shows a specific band for Caspase 3 in 0.2 mg/ml of HEK293 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Simple-Western-NB100-56112-img0009.jpg)
![Immunohistochemistry-Paraffin: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Caspase-3 expression in formalin-fixed, paraffin-embedded human reactive lymph node using NB100-56112 (Caspase-3 Antibody - (Pro and Active)) at 1:2000. Staining is seen in the apoptosis-prone germinal center B lymphocytes of follicles.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Immunohistochemistry-Paraffin-NB100-56112-img0008.jpg)
![Immunohistochemistry-Paraffin: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Analysis of Caspase-3 expression in formalin-fixed, paraffin-embedded human breast ductal carcinoma in situ using this antibody at 1:2000. Staining is seen in the the cancerous ducts, but not in the normal lobulus.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Immunohistochemistry-Paraffin-NB100-56112-img0007.jpg)
![ELISA Caspase-3 [Biotin]](http://images.novusbio.com/fullsize/dyc835-2_human-mouse-cleaved-caspase-3-asp175-duoset-ic-5-plate-elisa-1592020124056.jpg "ELISA Caspase-3 [Biotin]")
![<b>Biological Strategies Validation. </b>Immunohistochemistry-Paraffin: Caspase-3 Antibody (31A893) [NB100-56709] - Tissue section of normal human breast using 5 ug/mL concentration of . Very strong diffused as well as granular immunopositivity of Caspase 3 was observed specifically in the cytoplasmic of ductal /acinar epithelial cells.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-31A893-Immunohistochemistry-Paraffin-NB100-56709-img0004.jpg)
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: Caspase-3 Antibody (31A893) [NB100-56709] - Left panel: Untreated Jurkat cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton X-100. The cells were incubated with at 10 ug/mL overnight at 4C and detected with an anti-Mouse IgG Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-31A893-Immunocytochemistry-Immunofluorescence-NB100-56709-img0008.jpg)
![Western Blot: Caspase-3 Antibody (31A893) [NB100-56709] - Analysis for human Caspase-3 using HL60 lysates with Caspase-3 Antibody (31A893) at 2 ug/mL dilution. NB100-56709 only detects a 32 kD Caspase-3 corresponding to pro-Caspase-3.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-31A893-Western-Blot-NB100-56709-img0005.jpg)
![<b>Independent Antibodies Validation and Biological Strategies Validation.</b>Western Blot: Caspase-3 Antibody (31A893) [NB100-56709] - Analysis of Caspase-3 in Jurkat cells. Cells were treated with 2 uM staurosporine for different time periods. Caspase-3 activation is detected in Western blots by the presence of Caspase-3 cleavage fragments. These antibodies detect both pro (full-length) and active (cleaved) Caspase-3, depending on the treatment time points. A basal level of endogenous active Caspase-3 may be see in untreated Jurkat cells.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-31A893-Western-Blot-NB100-56709-img0006.jpg)
![Immunohistochemistry-Paraffin: Caspase-3 Antibody (31A893) [NB100-56709] - Caspase-3 was detected in immersion fixed paraffin-embedded sections of human bladder tissue using 5 ug/mL of mouse monoclonal Caspase-3 Antibody (31A893) (NB100-56709, Novus Biologicals), for 1 hour at room temperature followed by anti-mouse IgG VisUCyte HRP polymer (VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue).](http://images.novusbio.com/fullsize/Caspase-3-Antibody-31A893-Immunohistochemistry-Paraffin-NB100-56709-img0007.jpg)
![Western Blot: Caspase-3 Antibody (31A893) - BSA Free [NB100-56709] - Lemongrass extract is dependent on the production of oxidative stress to induce apoptosis. (E) E6-1 cells treated for 3 hrs with LG with or without NAC, lysed, & subjected to SDS-PAGE. Cells then transferred to a PVDF membrane & probed for the specific proteins. Bands visualized with a chemiluminescence reagent. Statistical calculations performed using Two-Way ANOVA multiple comparison for (A) & One-Way ANOVA multiple comparison for (B–C). **p < 0.01 vs. Control, ****p < 0.0001 vs. Control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.22502), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56709_mouse-monoclonal-caspase-3-antibody-31a893-31020241535657.jpg)
![Western Blot: Caspase-3 Antibody (31A893) - BSA Free [NB100-56709] - Functioning FADD protein is required to induce apoptosis in cancer cells treated with lemongrass extract(A) U-937 & (B) DN FADD Jurkat cells were treated for 12 hours & 48 hours, respectively, with the specified treatments, lysed, & subjected to SDS-PAGE. Cells were then transferred to a PVDF membrane & probed for the specific proteins. Bands were visualized with a chemiluminescence reagent. (C) DN FADD Jurkat cells were treated for 48 hours with the specified doses & stained with Annexin V & PI. Results were obtained using image-based cytometry with the Y-axis representative of percent of cells positive for Annexin V (green), PI (red), Annexin V & PI (yellow), or negative for both Annexin V & PI (blue). Values are expressed as a mean ± SD from three independent experiments. (D) DN FADD Jurkat cells were treated with H2DCFDA following treatments with paraquat (PQ), LG, or WT for 3 hours. Results were obtained using the image-based cytometry with the Y-axis representative of percent of cells positive for DCF. Values are expressed as a mean ± SD from three independent experiments. Statistical calculations were performed using Two-Way ANOVA multiple comparison for (C) & One-Way ANOVA multiple comparison for (D). ***p < 0.001 vs. Control, ****p < 0.0001 vs. Control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.22502), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56709_mouse-monoclonal-caspase-3-antibody-31a893-310202415525230.jpg)
![Western Blot: Caspase-3 Antibody (31A893) - BSA Free [NB100-56709] - Functioning FADD protein is required to induce apoptosis in cancer cells treated with lemongrass extract(A) U-937 & (B) DN FADD Jurkat cells were treated for 12 hours & 48 hours, respectively, with the specified treatments, lysed, & subjected to SDS-PAGE. Cells were then transferred to a PVDF membrane & probed for the specific proteins. Bands were visualized with a chemiluminescence reagent. (C) DN FADD Jurkat cells were treated for 48 hours with the specified doses & stained with Annexin V & PI. Results were obtained using image-based cytometry with the Y-axis representative of percent of cells positive for Annexin V (green), PI (red), Annexin V & PI (yellow), or negative for both Annexin V & PI (blue). Values are expressed as a mean ± SD from three independent experiments. (D) DN FADD Jurkat cells were treated with H2DCFDA following treatments with paraquat (PQ), LG, or WT for 3 hours. Results were obtained using the image-based cytometry with the Y-axis representative of percent of cells positive for DCF. Values are expressed as a mean ± SD from three independent experiments. Statistical calculations were performed using Two-Way ANOVA multiple comparison for (C) & One-Way ANOVA multiple comparison for (D). ***p < 0.001 vs. Control, ****p < 0.0001 vs. Control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.22502), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56709_mouse-monoclonal-caspase-3-antibody-31a893-310202415535124.jpg)
![Immunocytochemistry/Immunofluorescence: Caspase-3 Antibody [NBP1-90125] - Staining of human cell line U-251 MG shows localization to nucleoplasm and mitochondria. Antibody staining is shown in green.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-90125-img0015.jpg "Immunocytochemistry/Immunofluorescence: Caspase-3 Antibody [NBP1-90125] - Staining of human cell line U-251 MG shows localization to nucleoplasm and mitochondria. Antibody staining is shown in green.")
